FDA approves Ozempic® (semaglutide) as only GLP-1 RA to reduce the risk of worsening kidney disease and cardiovascular death in adults with type 2 diabetes and CKD
| | | |

FDA approves Ozempic® (semaglutide) as only GLP-1 RA to reduce the risk of worsening kidney disease and cardiovascular death in adults with type 2 diabetes and CKD

On Jan. 28, 2025, Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) has approved Ozempic® to…

U.S.  Implements New Export Controls to Address National Security Risks Related to Biotechnology
| | | | | | | | | | | | |

U.S. Implements New Export Controls to Address National Security Risks Related to Biotechnology

On Jan. 15, 2025, the U.S. Department of Commerce’s Bureau of Industry and Security (BIS) released an Interim…